These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

451 related items for PubMed ID: 18226677

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A Phase I study of the functional performance, safety and acceptability of the BufferGel Duet.
    Ballagh SA, Brache V, Mauck C, Callahan MM, Cochon L, Wheeless A, Moench TR.
    Contraception; 2008 Feb; 77(2):130-7. PubMed ID: 18226678
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Acceptability of a non-woven device for vaginal drug delivery of microbicides or other active agents.
    Joanis CL, Hart CW.
    AIDS Behav; 2010 Jun; 14(3):600-6. PubMed ID: 20049522
    [Abstract] [Full Text] [Related]

  • 8. Acceptability of Carraguard vaginal gel use among Thai couples.
    Whitehead SJ, Kilmarx PH, Blanchard K, Manopaiboon C, Chaikummao S, Friedland B, Achalapong J, Wankrairoj M, Mock P, Thanprasertsuk S, Tappero JW.
    AIDS; 2006 Nov 14; 20(17):2141-8. PubMed ID: 17086053
    [Abstract] [Full Text] [Related]

  • 9. Carraguard Vaginal Gel Safety in HIV-Positive Women and Men in South Africa.
    van de Wijgert JH, Braunstein SL, Morar NS, Jones HE, Madurai L, Strickfaden TT, Moodley M, Aboobaker J, Ndlovu G, Ferguson TM, Friedland BA, Hart CE, Ramjee G.
    J Acquir Immune Defic Syndr; 2007 Dec 15; 46(5):538-46. PubMed ID: 18193495
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women.
    Nel AM, Coplan P, van de Wijgert JH, Kapiga SH, von Mollendorf C, Geubbels E, Vyankandondera J, Rees HV, Masenga G, Kiwelu I, Moyes J, Smythe SC.
    AIDS; 2009 Jul 31; 23(12):1531-8. PubMed ID: 19550287
    [Abstract] [Full Text] [Related]

  • 12. Desired qualities and hypothetical contextual use of vaginal microbicides in a diverse sample of US women.
    Olsen ML, Cwiak CA, Koudelka C, Jensen JT.
    Contraception; 2007 Oct 31; 76(4):314-8. PubMed ID: 17900444
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Expanded safety and acceptability of the candidate vaginal microbicide Carraguard® in South Africa.
    Carraguard Phase II South Africa Study Team.
    Contraception; 2010 Dec 31; 82(6):563-71. PubMed ID: 21074021
    [Abstract] [Full Text] [Related]

  • 17. Safety and acceptability of 6% cellulose sulfate vaginal gel applied four times per day for 14 days.
    Doh AS, Ngoh N, Roddy R, Lai JJ, Linton K, Mauck C.
    Contraception; 2007 Sep 31; 76(3):245-9. PubMed ID: 17707724
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Vaginal gel formulation based on theaflavin derivatives as a microbicide to prevent HIV sexual transmission.
    Yang J, Li L, Jin H, Tan S, Qiu J, Yang L, Ding Y, Jiang ZH, Jiang S, Liu S.
    AIDS Res Hum Retroviruses; 2012 Nov 31; 28(11):1498-508. PubMed ID: 22867271
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.